40542 Federal Register / Vol. 63, No. 145 /Wednesday, July 29, 1998 / Notices

Settlement Agreement in Sarah Yules v.

United States of America, Civil Action

No. 95–10256–WGY (D. Mass.), was

preliminarily approved by the United

States District Court for the District of

Massachusetts on June 19, 1998. Final

approval of the proposed Settlement

Agreement is subject to the

requirements of 28 CFR 50.7.

In this case, Plaintiffs Sarah Yules and

Sandra Faxon, acting for themselves and

on behalf of proposed class of persons

in the Town of Mashpee, Massachusetts,

whose drinking water supplies had been

contaminated or threatened by

pollutants allegedly emanating from the

Massachusetts Military Reservation,

Barnstable County, Massachusetts

(‘‘MMR’’), filed suit in 1995 against,

among others, the United States

Department of Defense and the United

States National Guard Bureau (‘‘the

federal defendants’’). The suit asserted

claims under the Comprehensive

Environmental Response,

Compensation, and Liability Act, the

Resource Recovery and Conservation

Act, the Federal Clean Water Act, the

Federal Tort Claims Act, and state law.

Plaintiffs sought, among other things, an

injunction requiring the federal

defendants to abate any endangerment

caused by the alleged discharge of

pollutants from the MMR by connecting

class members to the public water

supply.

The United States and Plaintiffs have

now reached agreement on the terms of

a settlement of the claims in this case.

The Department of Justice will receive

written comments on the proposed

Settlement Agreement for a period of 30

days from the date of publication of this

notice. Comments should be addressed

to Joshua E. Swift, U.S. Department of

Justice, Environment & Natural

Resources Division, Environmental

Defense Section, P.O. Box 23986,

Washington, DC 20026, and refer to

Sarah Yules v. United States of

America, Civil Action No. 95–10246–

WGY (D. Mass.), DJ# 90–11–3–1506.

The Settlement Agreement may be

examined at the Clerk’s Office, United

States District Court for the District of

Massachusetts, 90 Devonshire Street,

Room 607, Boston, Massachusetts (617–

223–9152), or at the offices of Plaintiffs’

counsel, Shapiro, Haber & Urmy, 75

State Street, Boston, Massachusetts

(617–439–3939).

Letitia J. Grishaw,

Chief, Environmental Defense Section,

Environmental & Natural Resources Division.

[FR Doc. 98–20259 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Agency Information Collection

Activities: Proposed Collection;

Comment Request

ACTION: Notice of Information Collection

Under Review; Extension of a currently

approved collection; Controlled

Substances Import/Export Declaration—

DEA Form 236.

This proposed information collection

is published to obtain comments from

the public and affected agencies.

Comments are encouraged and will be

accepted until September 28, 1998.

Request written comments and

suggestions from the public and affected

agencies concerning the proposed

collection of information.

Your comments should address one or

more of the following four points:

1. evaluate whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency/component,

including whether the information will

have practical utility;

2. evaluate the accuracy of the

agencies/components estimate of the

burden of the proposed collection of

information including the validity of the

methodology and assumptions used;

3. enhance the quality, utility, and

clarity of the information to be

collected; and

4. minimum the burden of the

collection of information on those who

are respond, including through the use

of appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms

information technology, e.g., permitting

electronic submission of responses.

If you have comments, suggestions, or

need copy of the proposed information

collection instrument with instructions,

if applicable, or additional information,

please contact Patricia Good, 202–307–

7297, Chief, Policy and Liaison Section,

Office of Diversion Control, Drug

Enforcement Administration,

Washington, DC 20537.

Overview of this Information

(1) Type of information collection:

Extension of a currently approved

collection.

(2) The title of form/collection:

Controlled Substances Import/Export

Declaration—DEA Form 236.

(3) The agency form number, if any,

and the applicable component of the

Department sponsoring the collection:

Form No.: DEA Form 236.

Applicable component of the

Department sponsoring the collection:

Office of Diversion Control, Drug

Enforcement Administration, U.S.

Department of Justice.

(4) Affected public who will be asked

or required to respond, as well as a brief

abstract:

Primary: Business or other for-profit.

Other: None.

Abstract: DEA–236 provide the DEA

with control measures over the

importation and exportation of

controlled substances as required by

both domestic and international drug

control laws. Affected public consists of

businesses or other for profit

organizations.

(5) An estimate of the total number of

respondents and the amount of time

estimated for an average respondent to

respond/reply: 230 respondents. 12

responses per year × 15 minutes per

response = 3 hrs.

(6) An estimate of the total burden (in

hours) associated with the collection:

690 annual burden hours. 230

respondents × 3 hrs. per respondent per

year.

If additional information is required

contact: Mr. Robert B. Briggs, Clearance

Officer, United States Department of

Justice, Information Management and

Security Staff, Justice Management

Division, Suite 850, Washington Center,

1001 G. Street, NW, Washington, DC

20530.

Robert B. Briggs,

Department Clearance Officer, United States

Department of Justice.

[FR Doc. 98–20233 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on May 13, 1998,

American Radiolabeled Chemicals, Inc.,

11624 Bowling Green Drive, St. Louis,

Missouri 63146, made application by

letter to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below.

Drug Schedule

Dimethyltryptamine (7435) ........... I

Dihydromorphine (9145) ............... I

Cocaine (9041) ............................. II

Morphine (9300) ........................... II

The firm plans to bulk manufacture

small quantities of the listed controlled

substances as radiolabeled compounds.
Federal Register / Vol. 63, No. 145 /Wednesday, July 29, 1998 / Notices 40543

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistance Administrator,

Office of Diversion Control, Drug

Enforcement Admistration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than

September 28, 1998.

Dated: July 16, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–20175 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances, Registration

By Notice dated January 27, 998, and

published in the Federal Register on

February 14, 1998, (63 FR 18227),

Celgene Corporation, 7 Powder Horn

Drive, Warren, New Jersey 07059 made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as a bulk of manufacturer

of the basic classes of controlled

substances listed below

Drug Schedule

2,5-Dimethoxyamphatamine

(7396).

I

4-Methoxyamphetamine (7411) .... I

Amphetamine (1100) .................... II

Methylphenidate (1724) ................ II

The firm plans to manufacture

amphetamine for distribution of the

bulk active substances to its customers,

4-methoxyamphetamine as an

intermediate in the manufacture of a

non-controlled substance,

methylphenidate for product research

and development and 2,5-

dimethoxyamphetamine to develop,

manufacture and sell compounds to

pharmaceutical and agrochemical

industries.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Celgene Corporation to

manufacture the listed controlled

substances is consistent with the public

interest at this time. Therefore, pursuant

to 21 U.S.C. 823 and 28 CFR 0.100 and

0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: July 13, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–20177 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Registration

By Notice dated April 3, 1998, and

published in the Federal Register on

April 14, 1998, (63 FR 18227), Lilly del

Caribe, Inc., Chemical Plant, Kilometer

146.7, State Road 2, Mayaguez, Puerto

Rico 00680, made application to the

Drug Enforcement Administration

(DEA) to be registered as a bulk

manufacturer of dextropropoxyphene

(9273), a basic class of controlled

substance listed in Schedule II.

The firm plans to manufacture bulk

product for distribution to its customers.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Lilly del Caribe, Inc. to

manufacture dextropropoxyphene is

consistent with the public interest at

this time. Therefore, pursuant to 21

U.S.C. 823 and 28 CFR 0.100 and 0.104,

the Deputy Assistant Administrator,

Office of Diversion Control, hereby

orders that the application submitted by

the above firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: July 13, 1998.

John H. King.

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–20178 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances;

Registration

By Notice dated May 6, 1998, and

published in the Federal Register on

May 19, 1998, (63 FR 27588), Lonza

Riverside, 900 River Road,

Conshohocken, Pennsylvania 19428,

made application by renewal to the

Drug Enforcement Administration

(DEA) to be registered as an importer of

phenylacetone (8501), a basic class of

controlled substance listed in Schedule

II.

The firm is importing the

phenylacetone to manufacture

dextroamphetamine sulfate.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Lonza Riverside to import

phenylacetone is consistent with the

public interest and with United States

obligations under international treaties,

conventions, or protocols in effect on

May 1, 1971, at this time. Therefore,

pursuant to Section 1008(a) of the

Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations,

§ 1301.34, the above firm is granted

registration as an importer of the basic

class of controlled substance listed

above.

Dated: July 14, 1998.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 98–20176 Filed 7–28–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Application

Pursuant to § 1301.33(a) of Title 21 of

the Code of Federal Regulations (CFR),

this is notice that on May 12, 1998,

Novartis Pharmaceuticals Corp.,

Regulatory Compliance, 556 Morris

Avenue, Summit, New Jersey 07901,

made application by renewal to the

Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the Schedule II

controlled substance methylphenidate

(1724).

The firm plans to manufacture

finished product for distribution to its

customers

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the proposed registered.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administor, Office

of Diversion Control, Drug Enforcement